20:10 , Mar 1, 2019 |  BC Week In Review  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
01:30 , Mar 1, 2019 |  BC Week In Review  |  Financial News

After J&J retinal dea, MeiraGTx raises $80M for partnered programs

MeiraGTx Holdings plc (NASDAQ:MGTX) added $2.23 (17%) to $15.50 on Feb. 27 after the company raised $80 million in a private placement, which includes a $40 million equity investment from Johnson & Johnson Innovation -...
19:36 , Feb 27, 2019 |  BC Extra  |  Financial News

After J&J retinal deal, MeiraGTx raises $80M for unpartnered programs

MeiraGTx Holdings plc (NASDAQ:MGTX) added $2.23 (17%) to $15.50 on Wednesday after the company raised $80 million in a private placement, which includes a $40 million equity investment from Johnson & Johnson Innovation - JJDC...
00:14 , Feb 23, 2019 |  BC Extra  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
19:39 , Oct 10, 2018 |  BC Extra  |  Company News

Management tracks: Hamburg joins Alnylam board

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...
18:38 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Y-mAbs aims for $92M IPO

Y-mAbs Therapeutics Inc. (New York, N.Y.) filed to raise up to $92 million on Aug. 24 in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG. Y-mAbs hopes to submit...
22:14 , Aug 24, 2018 |  BC Extra  |  Financial News

Y-mAbs aiming for $92M IPO

Y-mAbs Therapeutics Inc. (New York, N.Y.) filed to raise up to $92 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG. Y-mAbs hopes to submit BLAs next year...
20:35 , Jun 6, 2018 |  BC Innovations  |  Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of...
21:59 , Jan 2, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Bioinformatic screens; cell-free assays A low-cost computational method for quantifying tumor cfDNA could identify cancer patients eligible for high-cost, whole-exome sequencing-based personalized medicine. The method quantifies tumor cfDNA in blood using the low-cost method...
21:30 , Nov 16, 2017 |  BC Innovations  |  Tools & Techniques

Internal logic

Instead of designing T cells to fight cancer, an MIT group is using synthetic biology to directly manipulate the tumor cells and make them more immunogenic. The big advantage, says the team, is that the...